Vilon

An ultra-short bioregulator peptide consisting of just two amino acids (lysine-glutamic acid) developed by the Khavinson research group. Despite its minimal size, Vilon demonstrates significant immunomodulatory and gene-regulatory effects, particularly on thymic function and T-cell immunity. It represents the smallest known peptide with documented bioregulatory activity.

• Interacts with DNA regulatory sequences to modulate immune gene expression
• Promotes thymic peptide production and T-cell differentiation
• Regulates cytokine balance for immune homeostasis

• Active autoimmune conditions (use with caution)
• Immunosuppressive therapy
• Pregnancy or breastfeeding

Store capsules at room temperature (15–25°C (59–77°F)). Injectable form: store at 2–8°C (36–46°F). Highly stable due to small size.

Research by the St. Petersburg Institute of Bioregulation and Gerontology has shown that Vilon can modulate expression of genes involved in immune regulation, cell differentiation, and apoptosis. Studies in aged animals demonstrated restored thymic structure and function. The dipeptide's ability to exert biological effects despite its tiny size challenges conventional pharmacological assumptions and has implications for oral peptide drug development. Published data spans over two decades of Russian bioregulatory research.